NanoImaging and Proteos Launched TrueCourse Biosciences
The new contract research organization provides integrated validation services for AI-designed drug discovery programs.
Updated on Sept. 22, 2026 in Biotech
Live Poll
Do you trust that AI-designed drugs are as safe and effective as traditional drug discovery methods?
NanoImaging Services and Proteos have launched TrueCourse Biosciences, an integrated contract research organization. The firm uses structural biology and biophysical assays to validate drug models created by artificial intelligence.
Why it matters
As drug discovery shifts toward AI-generated models, this entity provides the specialized lab capabilities required to confirm that these digital designs function as intended in physical biological environments.
TrueCourse Biosciences integrates structural biology and biophysical assays, including cryo-EM (electron microscopy of samples frozen at cryogenic temperatures) and SPR (surface plasmon resonance, a method for measuring molecular interactions), to validate AI-generated drug models.
The players
Dr. Lindsey Gottler
The Chief Executive Officer of TrueCourse Biosciences and former Chief Scientific Officer at Proteos.
Dr. Giovanna Scapin
The Chief Scientific Officer at TrueCourse Biosciences who oversees the organization's technical research direction.
NanoImaging Services
A provider of cryo-EM and microscopy services that has now integrated its operations into the new venture.
Proteos
A protein production specialist that has merged its capabilities with NanoImaging Services to form the new organization.
The details
The firm operates as a contract research organization, providing technical services including protein production, nanoparticle characterization, and X-ray crystallography, a technique used to determine the atomic structure of a crystal. By combining the infrastructure of NanoImaging Services and Proteos, the company aims to bridge the gap between AI-driven virtual design and the physical reality of drug development. Its laboratories are currently located in California, Massachusetts, and Michigan.
Timeline
September 22, 2026: Official publication of the company launch.
The Tech Race
This development follows the trend of specialized firms emerging to support AI-generated drug discovery programs. By integrating protein production and imaging under one roof, TrueCourse Biosciences seeks to secure its position in the competitive field of biophysical validation.
The firm will immediately provide validation services for biotech companies and academic researchers utilizing AI models in drug development. Future service expansion is expected as the company scales its operations in California, Massachusetts, and Michigan to meet market demand.
The takeaway
This launch highlights the growing demand for physical laboratory benchmarks that can prove the efficacy of AI-designed molecules. Watch for the company's service expansion milestones as a proxy for the broader adoption of AI in pharmaceutical R&D workflows.
Further reading
For more on the intersection of laboratory services and pharmaceutical development, explore our Biotech coverage.
Live Poll
Do you trust that AI-designed drugs are as safe and effective as traditional drug discovery methods?
